Gilead Sciences COO sells 100,000 Shares

In a legal filing with the Securities & Exchange Commission on July 9, Gilead Sciences has disclosed insider sales by its chief operating officer, John F Milligan on Tuesday, July 7. Milligan sold 100,000 shares of Gilead Sciences stock in a transaction totaling to $11,444,000.

Following the transaction, Milligan now directly owns 1,029,108 shares of the company's stock, valued at approximately $117,771,119.52. The present trading seems to be in continuation of the past six months transactions which have caused a change of -20.53% in the total insider ownership.

At Gilead Sciences, a 52 week low of $84.75 and a 52 week high of $123.37 has been recorded. The company has a market cap of $167.15 billion and a price-to-earnings ratio of 12.97.

Gilead Sciences is a research-based biopharmaceutical company working actively in North America, Europe and Asia Pacific in the fields of immunodeficiency virus, hepatitis B and C and cardiovascular/metabolic and respiratory conditions.

Gilead Sciences share prices witnessed sharp instability on Friday, with the shares opening for trading at $114.88 and ending the session at $113.74. Recording a gain of 0.34% or 0.38 points, the trading volume jumped to 9,703,375 shares.

GILD shares have attracted varied analysts' reviews, the Bank of America analyst's gave an 'underperform' rating to the company on July 6th, raising their price target on shares of Gilead Sciences from $94.00 to $101.00. Analysts at Vetr upgraded shares of Gilead Sciences from 'hold' to a 'buy' position on July 2 while Zacks analysts downgraded shares of Gilead Sciences from a 'strong-buy' rating to a 'hold' rating on July 1.